VanEck Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $622M | Sell |
10,257,215
-296,506
| -3% | -$17.3M | 0.47% | 38 |
|
|
2025
Q4 | $569M | Buy |
10,553,721
+693,806
| +7% | +$33.4M | 0.47% | 40 |
|
|
2025
Q3 | $445M | Buy |
9,859,915
+5,933,805
| +151% | +$277M | 0.41% | 53 |
|
|
2025
Q2 | $182M | Sell |
3,926,110
-1,067,008
| -21% | -$52.4M | 0.21% | 103 |
|
|
2025
Q1 | $305M | Sell |
4,993,118
-4,076,708
| -45% | -$238M | 0.39% | 67 |
|
|
2024
Q4 | $513M | Sell |
9,069,826
-863,765
| -9% | -$48.3M | 0.66% | 34 |
|
|
2024
Q3 | $527M | Buy |
9,933,591
+781,385
| +9% | +$36.7M | 0.66% | 34 |
|
|
2024
Q2 | $380M | Buy |
9,152,206
+1,203,033
| +15% | +$53.8M | 0.54% | 45 |
|
|
2024
Q1 | $431M | Buy |
7,949,173
+3,918,234
| +97% | +$200M | 0.65% | 37 |
|
|
2023
Q4 | $207M | Buy |
4,030,939
+3,579,324
| +793% | +$188M | 0.38% | 74 |
|
|
2023
Q3 | $26.2M | Buy |
451,615
+83,599
| +23% | +$5.12M | 0.06% | 196 |
|
|
2023
Q2 | $23.5M | Buy |
368,016
+27,244
| +8% | +$1.83M | 0.05% | 216 |
|
|
2023
Q1 | $23.6M | Sell |
340,772
-145,080
| -30% | -$10.2M | 0.05% | 220 |
|
|
2022
Q4 | $35M | Sell |
485,852
-26,657
| -5% | -$2.01M | 0.09% | 176 |
|
|
2022
Q3 | $36.4M | Buy |
512,509
+18,270
| +4% | +$1.33M | 0.11% | 168 |
|
|
2022
Q2 | $38.1M | Sell |
494,239
-1,343,021
| -73% | -$102M | 0.1% | 178 |
|
|
2022
Q1 | $134M | Sell |
1,837,260
-1,530,832
| -45% | -$103M | 0.28% | 94 |
|
|
2021
Q4 | $210M | Buy |
3,368,092
+267,069
| +9% | +$15.7M | 0.49% | 50 |
|
|
2021
Q3 | $183M | Buy |
3,101,023
+317,524
| +11% | +$20.9M | 0.46% | 50 |
|
|
2021
Q2 | $186M | Buy |
2,783,499
+415,920
| +18% | +$27.1M | 0.44% | 53 |
|
|
2021
Q1 | $149M | Buy |
2,367,579
+392,331
| +20% | +$24.4M | 0.41% | 56 |
|
|
2020
Q4 | $123M | Buy |
1,975,248
+148,632
| +8% | +$9.14M | 0.36% | 61 |
|
|
2020
Q3 | $110M | Buy |
1,826,616
+776,505
| +74% | +$46.7M | 0.35% | 53 |
|
|
2020
Q2 | $61.7M | Buy |
1,050,111
+36,906
| +4% | +$2.21M | 0.22% | 92 |
|
|
2020
Q1 | $56.5M | Sell |
1,013,205
-830,010
| -45% | -$50.7M | 0.29% | 81 |
|
|
2019
Q4 | $118M | Buy |
1,843,215
+275,262
| +18% | +$15.8M | 0.46% | 36 |
|
|
2019
Q3 | $79.5M | Buy |
1,567,953
+685,314
| +78% | +$32.2M | 0.37% | 50 |
|
|
2019
Q2 | $40M | Buy |
882,639
+154,830
| +21% | +$7.21M | 0.19% | 111 |
|
|
2019
Q1 | $34.7M | Buy |
727,809
+35,945
| +5% | +$1.79M | 0.17% | 128 |
|
|
2018
Q4 | $36M | Buy |
691,864
+45,599
| +7% | +$2.45M | 0.18% | 113 |
|
|
2018
Q3 | $40.1M | Sell |
646,265
-17,535
| -3% | -$1.04M | 0.2% | 121 |
|
|
2018
Q2 | $36.7M | Buy |
663,800
+201,430
| +44% | +$10.9M | 0.17% | 125 |
|
|
2018
Q1 | $29.2M | Sell |
462,370
-291,488
| -39% | -$18.8M | 0.15% | 137 |
|
|
2017
Q4 | $46.2M | Sell |
753,858
-37,417
| -5% | -$2.34M | 0.23% | 100 |
|
|
2017
Q3 | $50.4M | Buy |
791,275
+5,451
| +0.7% | +$318K | 0.26% | 82 |
|
|
2017
Q2 | $43.8M | Buy |
785,824
+29,369
| +4% | +$1.6M | 0.24% | 86 |
|
|
2017
Q1 | $41.1M | Buy |
756,455
+116,064
| +18% | +$6.37M | 0.18% | 102 |
|
|
2016
Q4 | $37.4M | Buy |
640,391
+257,822
| +67% | +$14.1M | 0.19% | 95 |
|
|
2016
Q3 | $20.6M | Buy |
382,569
+202,675
| +113% | +$13M | 0.1% | 135 |
|
|
2016
Q2 | $13.2M | Sell |
179,894
-17,808
| -9% | -$1.26M | 0.07% | 174 |
|
|
2016
Q1 | $12.6M | Sell |
197,702
-66,519
| -25% | -$4.19M | 0.09% | 154 |
|
|
2015
Q4 | $18.2M | Buy |
264,221
+5,890
| +2% | +$389K | 0.14% | 142 |
|
|
2015
Q3 | $15.3M | Sell |
258,331
-7,725
| -3% | -$490K | 0.12% | 149 |
|
|
2015
Q2 | $17.7M | Buy |
266,056
+42,033
| +19% | +$2.77M | 0.1% | 160 |
|
|
2015
Q1 | $14.4M | Sell |
224,023
-24,412
| -10% | -$1.53M | 0.08% | 182 |
|
|
2014
Q4 | $14.7M | Sell |
248,435
-105,116
| -30% | -$5.93M | 0.09% | 169 |
|
|
2014
Q3 | $18.1M | Buy |
353,551
+30,820
| +10% | +$1.54M | 0.1% | 156 |
|
|
2014
Q2 | $15.7M | Buy |
322,731
+65,717
| +26% | +$3.24M | 0.07% | 166 |
|
|
2014
Q1 | $13.4M | Buy |
257,014
+7,092
| +3% | +$377K | 0.07% | 176 |
|
|
2013
Q4 | $13.3M | Sell |
249,922
-27,356
| -10% | -$1.39M | 0.07% | 163 |
|
|
2013
Q3 | $12.8M | Buy |
277,278
+18,833
| +7% | +$827K | 0.07% | 154 |
|
|
2013
Q2 | $11.6M | Buy |
+258,445
| New | +$11.2M | 0.06% | 152 |
|
Other funds holding BMY
VCM
VPM
VanEck Associates's BMY Position: Q1 2026 in Review
VanEck Associates reduced its Bristol-Myers Squibb (BMY) stake by 2.8% in Q1 2026, selling an estimated $17.3M and leaving 10,257,215 shares worth $622M. The position accounts for 0.47% of the portfolio, ranked #38.
VanEck Associates first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- VanEck Associates held 10,257,215 shares of Bristol-Myers Squibb worth $622M as of Q1 2026.
- VanEck Associates sold 296,506 Bristol-Myers Squibb shares in Q1 2026, an estimated $17.3M.
- Bristol-Myers Squibb made up 0.47% of VanEck Associates's portfolio in Q1 2026, its #38 holding.
- VanEck Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.